Status : investigational


SB-681323 is a p38 MAP-kinase inhibitor that has potential uses in inflammatory conditions such as RA(Rheumatoid Arthritis). Previous p38 MAP-kinase inhibitors have been hindered in development by liver toxicity. Methotrexate (common treatment for RA patients) also has potential liver toxicity.


Rheumatoid arthritis and Chronic obstructive pulmonary disease

Mechanism Of Action

This drug reduces the levels of proinflammatory cytokines and chemokines and reduce cellular infiltration to sites of inflammation, thereby reducing local damage. In diseases such as RA and IBD, TNFα blockade through either anti-TNFα antibodies or use of soluble TNFα receptors. Inhibition of p38α offers significant inhibition of TNFα, and cytokines such as IL-1β and IL-6, which offer additional therapeutic efficacy.

Chemical Classification

Calculated Property

kind Value Source

Target within organism

  • Tumor necrosis factor : in Human
  • Interleukin-1 beta : in Human
  • Interleukin-6 : in Human